Literature DB >> 7361240

Relationship of lesion size to survival in patients with stage IB squamous cell carcinoma of the cervix uteri treated by radiation therapy.

H D Homesley, M Raben, D D Blake, C R Ferree, M S Bullock, E B Linton, F C Greiss, A L Rhyne.   

Abstract

Forty-five patients with Stage IB squamous cell carcinoma of the cervix uteri were treated with radiation therapy alone. The five year actuarial survival rate of the 22 patients in group 1 in whom the tumor was less than 4 centimeters in diameter was 95 per cent, which was significantly higher than the 67 per cent survival rate in the 23 patients in group 2 with bulky lesions greater than or equal to 4 centimeters in diameter, p less than 0.05. These results of radiation therapy are consistent with surgical results recently reported and indicate that patients with bulky lesions, especially those tumors greater than or equal to 4 centimeters in size, comprise a high risk subset within the Stage IB classification. A new classification is proposed in which bulky lesions are designated Stage IC, advanced overt, so that such high risk patients might be identified and more efficacious treatment regimens might be developed.

Entities:  

Mesh:

Year:  1980        PMID: 7361240

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  2 in total

1.  Value of pelvic examination and imaging modality for the evaluation of tumor size in cervical cancer.

Authors:  Yoo-Kyung Lee; Seung-Su Han; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2008-06-20       Impact factor: 4.401

2.  Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy.

Authors:  Oliver Zivanovic; Kaled M Alektiar; Yukio Sonoda; Qin Zhou; Alexia Iasonos; William P Tew; John P Diaz; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2008-09-06       Impact factor: 5.482

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.